Adial Pharmaceuticals, Inc. (ADIL) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Charlottesville, VA, United States. El CEO actual es Cary John Claiborne.
ADIL tiene fecha de IPO 2018-07-27, 5 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $1.52M.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
